Regeneron and Sanofi to Appeal Patent Decision

18.03.2016 - Drugmakers Regeneron Pharmaceuticals and Sanofi have said they will appeal a decision by a US federal jury that their cholesterol drug Praluent (alirocumab) infringes patents owned...